Rapamune is used with other medicines to prevent kidney transplant rejection. The main ingredient of the drug is Sirolimus, which belongs to the group of immunosuppressive drugs. Medicines work to weaken your body's defense system (immune system) to help your body accept the newly transplanted organs.

Kidney transplant rejection is a phenomenon that can occur in people who do not comply with treatment, often skip doses of medication and forget to have regular health check-ups. Therefore, patients need to pay attention to these things to minimize the risk of transplant rejection.

New-onset inflammatory bowel disease after transplantation typically occurs late in the follow-up period, with a median delay of 91 months. Clinical manifestations of new-onset inflammatory bowel disease are similar to those occurring in the general population, including bloody diarrhea and abdominal pain.

Graft-versus-host disease in kidney transplant recipients is extremely rare. The pathogenesis of graft-versus-host disease is not fully understood, but it may be triggered by destruction of host tissues through a number of different mechanisms involving donor cytotoxic T cells.

When a patient with chronic kidney disease reaches the end stage, kidney transplant and replacement surgery is an almost mandatory medical intervention (except in cases where the patient is not in good health). However, kidney transplant treatment can leave many complications if there is no scientific care and treatment.